AstraZeneca Pharma India announced that it will launch Eculizumab (Soliris) in August 2025 in India.
Eculizumab (Soliris) is indicated for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS) to inhibit complement - mediated thrombotic microangiopathy.
Powered by Capital Market - Live News